XLO Xilio Therapeutics Inc. Forecast, Technical & Fundamental Analysis
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer... Show more
XLO is expected to report earnings to -57 cents per share on August 12
Q2'26
Est.
$-0.58
Q1'26
Missed
by $0.51
Q4'25
Beat
by $0.88
Q3'25
Missed
by $0.06
Q2'25
Missed
by $0.06
The last earnings report on May 12 showed earnings per share of -57 cents, missing the estimate of -6 cents. With 43.91K shares outstanding, the current market capitalization sits at 60.16M.
A.I.dvisor tells us that XLO and VYGR have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XLO and VYGR's prices will move in lockstep.
The 10-day RSI Oscillator for XLO moved out of overbought territory on June 25, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 16 instances where the indicator moved out of the overbought zone. In of the 16 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
XLO broke above its upper Bollinger Band on June 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for XLO entered a downward trend on June 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 15, 2026. You may want to consider a long position or call options on XLO as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for XLO just turned positive on June 15, 2026. Looking at past instances where XLO's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
XLO moved above its 50-day moving average on June 12, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for XLO crossed bullishly above the 50-day moving average on June 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XLO advanced for three days, in of 191 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.810) is normal, around the industry mean (21.001). P/E Ratio (0.000) is within average values for comparable stocks, (36.006). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). XLO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.967) is also within normal values, averaging (368.009).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. XLO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XLO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
